TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Dialyzer Assessment: Venous Header Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental area under the 2 hour blood glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in MRI Osteoarthritis Knee Score (MOAKS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-utility analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Social Anxiety Scale total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thickness of the sinus mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early diagnosis of bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of exercise sessions attended
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in blepharitis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of mRNAs of 18 genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TSIH incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Anti-Drug Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Biomarker-positive Immune Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Perceived Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in General Anxiety and Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Health Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADHD-RS-5 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Organ-space surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Serum Platelet Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants free from HIV-transmission risk
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in 12 lead ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Longest Duration of Abstinence From Cocaine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Degree of obstructed defecation syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in SFU Grade of Hydronephrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in strength of the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of patients with epithelial defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Baricitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve From Time Zero to Infinity [AUC (0-∞)] of Baricitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of New Inflammatory MRI Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Incidence of pterygium recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Bone quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety of Trogarzo
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of uterine malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants With Venous Thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Asthma control rate change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Milligram tolerated food allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Intracyclic Bleeding at Cycle 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescent Depression Knowledge Questionnaire (ADKQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: adverse effect
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adhesion Reformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The American Fertility Society Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pictorial Blood Loss Assessment Chart Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of solicited and unsolicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Extent of force while knot tying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of time having low blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of Aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vascular endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in aortic stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: perceived health status (patients only)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Thongprasom sign scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Health- Related Quality of Life index (OHIP-14)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement of joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Patients Experiencing Feasibility Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first event - all cause death
Endpoint domain: Mortality/survival
Primary endpoint: Time to first event - cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Time to first event - all cause hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without PSA progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean change in macular ganglion cell and inner plexiform layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized Ratio Between Mean IOP and Mean Arterial Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BBB intactness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Viral Load-Time Curve (VL-AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Telemedical home blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fit to the Peristomal Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Hot Flash Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Hot Flash Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in peak lactate/pyruvate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change on The Revised Child Anxiety and Depression Scale-30 (RCADS-30)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change on The Anxiety Scale for Children and Adolescents (EAN)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change on The Depression Questionnaire for Children and Adolescents (CDN)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Patients With a 3-point Reduction in QMG Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating Endothelial Cell (CEC) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Responders to ACR 20 at Day 180
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Immunoglobulin A (IgA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of specific antibodies in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of viral DNA in blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Brain imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessment of symptoms and daily functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ki-67 expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PTSD symptoms measured by Child Post Traumatic Stress Scale (CPSS-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD symptoms measured by Children's Revised Impact of Event Scale (CRIES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD symptoms measured by Clinician Administered PTSD Scale for Children and Adolescents (CAPS-CA-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in incident new vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in day long glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in day long insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Symptom Score (GSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in BUN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of Life (QOL) according to EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (QOL) according to Bariatric Analysis and Reporting System (BAROS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (QOL) according to Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Attentional Bias to chocolate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extremity volumetric measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Discontinued From the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Evidence of disease confirmed by surgery or biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: time of reconstruction during operations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: change of potential of hydrogen (pH) in remnant stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: amount of blood loss during operations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage Change From Baseline of Thigh Muscle Volume (TMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Absence of Gastrointestinal (GI) Leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: occurrence of intraoperative floppy iris syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative tear functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in menopause symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-Free Survival (DFS) at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: number of ACF identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: size of ACF identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: location of ACF identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-meter walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of DLTs during Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious and nonserious treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed drug concentration in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dapagliflozin Maximum Observed Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dapagliflozin Minimum Observed Plasma Concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oral health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of Participants With Controlled Acute Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adapted Measure of Participation in Conversation (MPC): Interaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Adapted Measure of Participation in Conversation (MPC): Transaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Interactional Network Tool (INT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hypoventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cognitive impairment assessment scale-HVLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive impairment assessment scale-SDMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive impairment assessment scale-JLO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of rifaximin 600 mg QD
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Hamilton Rating Scale for Depression (HRSD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Airway Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject mortality
Endpoint domain: Mortality/survival
Primary endpoint: Recovery time of moderate neuromuscular blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Family planning uptake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gut metagenomes at the bacteria species level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCL-5 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of dropouts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of refusals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Discontinued Because of an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Week 52 on the Young-Mania Rating Scale (Y-MRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 52 on the Montgomery Asberg Depression Rating Scale (MADRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of latent tuberculosis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensory block assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of patients with stable sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Physical Activity at 4 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Physical Activity at 8 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disease free survival at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Prevention and treatment effectiveness for Osteopenia of Prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acceptability of exercise program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of completed exercise tests and questionnaires
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ESQ IV factor scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change rate of MSSBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved local control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamics of the Main Veno-specific Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Severity of Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in smoking habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline NIHSS at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline fasting blood sugar at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline p-C-peptide at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Police Interaction Assessment Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Scalar Position of Electrode Array
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of exploitable ex vivo tumor, blood and urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in genomic and immune biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: soft tissue effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of neutrophil recovery of ≥ 500/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With VRE Decolonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With an Adverse Event (AE); Severe Adverse Event (SAE); and Newly Acquired Transmissible Infectious Diseases Which Are Considered Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as assessed by recording adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum concentration (Cmax) of ASP8477 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to attain Cmax (tmax) of ASP8477 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune T Cell Subsets and Immunophenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes